Search clinical trials for: GDC-0032

Total 2204 results

Genentech, Inc.

Completed

A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Korea, Republic of, Spain, Taiwan, Bulgaria, Colombia, Argentina, Brazil, Mexico, United Kingdom, Chile, Germany
Genentech, Inc.

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Metastatic Prostate Cancer | Advanced Prostate Cancer

Korea, Republic of, United States, Australia
Genentech, Inc.

Completed

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma

United States, Australia
Genentech, Inc.

Completed

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Urticaria

United States, Germany, Canada
Genentech, Inc.

Completed

A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants

Healthy Volunteer

United Kingdom
Lisa Bax
Roche Pharma AG; Genentech, Inc.

Terminated

Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) (HIPPoS)

Pancreatic Ductal Adenocarcinoma

United Kingdom
National Cancer Institute (NCI)

Completed

GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment

Recurrent Childhood Medulloblastoma

United States
Genentech, Inc.

Completed

A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

Hepatic Insufficiency

United States
Genentech, Inc.

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants

Healthy Volunteers

United Kingdom
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants

Healthy Volunteer

United States
Genentech, Inc.

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma

Basal Cell Carcinoma

United States
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

Prevention of Graft Rejection After Organ Transplantation

China
National Cancer Institute (NCI)

Completed

Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma

Recurrent Childhood Medulloblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Vismodegib in Treating Patients With Advanced Chondrosarcomas

Mesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Clear Cell Chondrosarcoma | Locally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Primary Central Chondrosarcoma

France
Hoffmann-La Roche

Recruiting

A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer (EndomERA)

Endometrial Cancer

United States, Canada, Italy, Poland
NYU College of Dentistry
Genentech, Inc.

Completed

A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors (KCOT)

Keratocystic Odontogenic Tumor

United States
The Lymphoma Academic Research Organisation
Roche Pharma AG

Terminated

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia (VISMOLY)

Chronic Lymphocytic Leukemia | Primary Central Nervous System Lymphoma | Diffuse Large B-cell Lymphoma | Indolent Non-hodgkin Lymphoma

France
Genentech, Inc.
National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center...

Completed

GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Wake Forest University Health Sciences

Active, not recruiting

SNIFF Multi-Device Study 2

Cognitive Impairment | Mild Cognitive Impairment

United States
Genentech, Inc.

Completed

A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants

Healthy Volunteers
National Cancer Institute (NCI)

Completed

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
Genentech, Inc.

Completed

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy

Breast Cancer

Belgium, Israel, United States, Spain, Denmark, Germany, Hong Kong, Russian Federation, Australia, New Zealand, Korea, Republic of, Malaysia, Singapore, Italy, Czech Republic, France, Peru, Canada, United Kingdom, Chile, Thailand, Argentin... and more
Hoffmann-La Roche

Completed

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

Solid Tumor, Unspecified, Adult

United States
Genentech, Inc.

Completed

A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

Neoplasms

United States, Spain
Genentech, Inc.

Completed

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

Basal Cell Carcinoma

Australia, France, United States, Germany, Belgium, United Kingdom
Avalo Therapeutics, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Non-Eosinophilic Asthma

United States
Genentech, Inc.

Completed

A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Solid Cancers

United States
Genentech, Inc.

Withdrawn

A Study to Assess the Relative Bioavailability And Food Effect of a Tablet Formulation of GDC-0276 in Healthy Participants

Healthy Volunteer

United Kingdom
CuraSen Therapeutics, Inc.

Withdrawn

A Study of CST-2032 in Subjects With Cognitive Impairment

Mild Cognitive Impairment (MCI) | Parkinson Disease (PD)
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers

Prevention of Herpes Zoster (HZ)

Australia
Hoffmann-La Roche

Completed

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)

Solid Tumors

United States, Spain, Germany, France, Israel, Italy, United Kingdom
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Acute Lung Injury | ARDS | COVID-19 Pneumonia

United States
UCSF Benioff Children's Hospital Oakland
Genentech, Inc.

Completed

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS) (GDC-0449)

Basal Cell Nevus Syndrome | Gorlin Syndrome

United States
Eden Miller
Pendulum Therapeutics

Unknown

Effects on Glycemic Control of WBF-0031 in Subjects With Abnormal Glucose Tolerance

Abnormal Glucose Tolerance

United States
Pear Therapeutics, Inc.

Active, not recruiting

A Remote, 9-week Insomnia Treatment Trial to Collect Real World Data for a Digital Therapeutic (DREAM)

Chronic Insomnia

United States
Debiopharm International SA

Completed

Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma

Neoplasms | Lymphoma | Cancer | Solid Tumors

France
Genentech, Inc.

Completed

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

Ovarian Cancer
Genentech, Inc.
Seragon Pharmaceuticals

Completed

A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Breast Cancer

Spain, United States
Genentech, Inc.

Recruiting

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Chronic Refractory Cough (CRC) With Non-atopic Asthma | CRC With Atopic Asthma | Unexplained Chronic Cough | CRC With Chronic Obstructive Pulmonary Disease | CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

United States, Australia, United Kingdom, Canada
Avalo Therapeutics, Inc.

Terminated

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

United States
Janssen Research & Development, LLC

Completed

First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Vyluma, Inc.
Syneos Health

Active, not recruiting

CHAMP: Study of NVK-002 in Children With Myopia

Myopia

United States, Hungary, Ireland, Netherlands, Spain, United Kingdom
Shenzhen NewDEL Biotech, Co., Ltd
Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults

Healthy
Genentech, Inc.

Completed

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers

Healthy Volunteer

United States
Turning Point Therapeutics, Inc.

Active, not recruiting

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)

Advanced Solid Tumor | Metastatic Solid Tumors | MET Gene Alterations

United States, France, Korea, Democratic People's Republic of, Korea, Republic of, Spain
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Inflammation | Rheumatoid Arthritis

United States, Mexico, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Hungary, Poland, United Kingdom
Techfields Pharma Co. Ltd

Withdrawn

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Lumbar Spine

Pain, Back | Osteoarthritis of the Lumbar Spine

Search clinical trials for: GDC-0032

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations